Restricted accessResearch articleFirst published online 2006-07
Association of Two Polymorphisms in the Peroxisome Proliferator-Acativated Receptor-γ Gene With Adenomyosis,Endometriosis,and Leiomyomata in Japanese Women
Objective:The peroxisome proliferator-activated receptor-γ (PPAR-γ) is a nuclear hormone receptor that plays an important role in many diseases. This study investigated whether two polymorphisms (Pro12Ala in exon B and C161T in exon 6) of the PPAR-γ2 gene are related to adenomyosis, endometriosis, or leiomyomata.
Methods:A total of 390 patients with adenomyosis, endometriosis, and/or leiomyomata were classified into four groups: 103 patients with adenomyosis (21 adenomyosis only and 82 adenomyosis with endometriosis and/or leiomyomata), 95 patients with endometriosis only, 100 patients with leiomyomata only, and 92 patients with endometriosis and leiomyomata.
Results:There was no association between distribution of genotype or allele frequencies for the PPAR-γ Pro12Ala polymorphism and the presence of adenomyosis, endometriosis, and/or leiomyomata. However, compared with results for controls, the PPAR-γ 161CC genotype and 161C allele frequencies were significantly increased in patients with adenomyosis (genotype: χ2 = 9.185, corrected P value [Pc] = .0169; allele: χ2 = 8.337, Pc = .0155) and in patient with endometriosis (genotype: χ2 = 6.748, Pc = .0375; allele: χ2 = 6.413, Pc = .0453).
Conclusion:The results suggest that the PPAR-γ 161CC genotype could be a genetic risk factor for adenomyosis and endometriosis, whereas the Pro12Ala polymorphism was not associated with these estrogen-dependent benign uterine diseases in a Japanese population.
1. Simpson JL, Elias S, Malinak LR, Buttram VC Jr: Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol1980;137:327-331.
2.
2. Kennedy S. The genetics of endometriosis. Eur J Obstet Gynecol Reprod Biol1999;82:129-133.
3.
3. Gross KL, Morton CC. Genetics and the development of fibroids. Clin Obstet Gynecol2001;44:335-349.
4.
4. Kitawaki J, Obayashi H, Ishihara H, et al. Oestrogen receptoralpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Hum Reprod2001;16:51-55.
5.
5. Kitawaki J, Obayashi H, Ohta M, et al. Genetic contribution of the interleukin-10 promoter polymorphism in endometriosis susceptibility. Am J Reprod Immunol2002;47:12-18.
6.
6. Kitawaki J, Obayashi H, Kado N, et al. Association of HLA class I and class II alleles with susceptibility to endometriosis. Hum Immunol2002;63:1033-1038.
7.
7. Kado N, Kitawaki J, Obayashi H, et al. Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Hum Reprod2002;17:897-902.
8.
8. Kitawaki J, Koshiba H, Kitaoka Y, et al. Interferon-gamma gene disnucleotide (CA) repeat and interleukin-4 promoter region (-590C/T) polymorphisms in Japanese patients with endometriosis. Hum Reprod2004;19:1765-1769.
9.
9. Teramoto M, Kitawaki J, Koshiba H, et al. Genetic Contribution of tumor necrosis factor (TNF)-alpha gene promoter (-1031, -863 and -857) and TNF receptor 2 gene polymorphisms in endometrosis susceptibility. Am J Reprod Immunol2004;51:352-357.
10.
10. Hornung D, Waite LL, Ricke EA, Bentzien F, Wallwiener D, Taylor RN. Nuclear peroxisome proliferator-activated receptors alpha and gamma have opposing effects on monocyte chemotaxis in endometriosis. J Clin Endocrinol Metab2001;86:3108-3114.
11.
11. Pritts EA, Zhao D, Ricke E, Waite L, Taylor RN. PPAR-gamma decreases endometrical stromal cell transcription and translation of RANTES in vitro. J Clin Endocrinol Metab2002;87:1841-1844.
12.
12. Wanichkul T, Han S, Huang RP and Sidell N. Cytokine regulation by peroxisome proliferator-activated receptor gamma in human endometrial cells. Fertil Steril2003;79:763-769.
13.
13. Houston KD, Copland JA, Broaddus RR, Gottardis MM, Fischer SM, Walker CL. Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma. Cancer Res2003;63:1221-1227.
14.
14. Gunin AG, Bitter AD, Demakov AB, Vasilieva EN, Suslonova NV. Effects of peroxisome proliferator activated receptor-alpha and -gamma agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus. J Endocrinol2004;182:229-239.
15.
15. Beamer BA, Negric C, Yen CJ, et al. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene. Biochem Biophys Res Commun1997;233:756-759.
16.
16. Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: Identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun1997;241:270-274.
17.
17. Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes2002;51:2341-2347.
18.
18. Meirhaeghe A, Fajas L, Helbecque N, et al. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet1998;7:435-440.
19.
19. Ogawa S, Urano T, Hosoi T, et al. Association of bone mineral density wiht a polymorphism of the peroxisome proliferation-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun1999;260;122-126.
20.
20. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Al polymoprhism is associated with decreased risk of type 2 diabetes. Nat Genet2000;26:76-80.
21.
21. Mori H, Ikegami H, Kawaguchi Y, et al. The Pro12 →Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: Possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes2001;50:891-894.
22.
22. Hara K, Okada T, Tobe K, et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun2000;271:212-216.
23.
23. Orio F Jr, Matarese G, Di Biase S, et al. Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab2003;88:5887-5892.
24.
24. Dogan S, Machicao F, Wlalwiener D, Haering HU, Diedrich K, Hornung D. Association of peroxisome proliferator-activated receptor gamma 2 Pro-12-Ala polymoprhism with endometriosis. Fertil Steril2004;81:1411-1413.
25.
25. American Society for Reproductive Medicine: Revised American Society for Reproductive Medicine classification of endometrosis: 1996. Fertil Steril1997;67:817-821.
26.
26. Machin D, Cambel M, Fayers P, Pinol A. Comparing independent groups for binary, ordered categorical and continuous data. In: Sample size tables for clinical studies. 2nd ed.Oxford, UK: Blackwell Science, 1997:18-78.
27.
27. Vigouroux C, Fajas L, Khallouf E, et al. Human peroxisome proliferator-activated recpetor-gamma2: Genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes1998;47:490-492.
28.
28. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferation activated receptor gamma and diabetes mellitus. Biochem Biophys Res Commun1999;254;450-453.
29.
29. Smith WM, Zhou XP, Kurose K, et al. Opposite association of two PPARG variants with cancer: Overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases. Hum Genet2001;109:146-151.
30.
30. Cho YM, Ritchie MD, Moore JH, et al. Multificator-dimensionality reduction shows a two-locus interaction associated with type 2 diabetes melltius. Diabetologia2004;47:549-554.
31.
31. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet2001;69:138-147.
